

Not for distribution to United States newswire services or for dissemination in the United States.  
The Canadian National Stock Exchange has not approved nor disapproved the contents of this press release.

## MERUS LABS INTERNATIONAL INC.

MERUS LABS INTERNATIONAL INC. ANNOUNCES \$2.0 MILLION NON-BROKERED PRIVATE  
PLACEMENT

VANCOUVER, February 23, 2011

CNSX Symbol: MR

**Merus Labs International Inc.** ("Merus" or the "Company") has agreed to a non-brokered private placement with Powerone Capital Markets Limited to issue up to 10 million units at the price of 20 cents per unit, for maximum gross proceeds of \$2.0million.

The units will consist of one common share of the Company and one share purchase warrant. Each warrant shall entitle the holder to purchase an additional common share of the Company at a price of 40 cents per share for a period of two years from the date of closing. The proposed financing is expected to close on or before March 11, 2011.

A finder's fee in connection with this offering will be paid. The finder's fee will consist of an 8-per-cent cash commission and a finder's warrant equal to 10 per cent of the number of units referred. Each finder's option warrant shall be exercisable into one unit at a price of 20 cents per unit for a period of two years from the date of closing. All securities issued pursuant to this offering will be subject to a four-month hold period from the date of closing.

Proceeds from the private placement will be used primarily to launch the Company's line of wound care products, to acquire a certain legacy product and for its general working capital. Merus currently has a non-binding term sheet to acquire a certain legacy product for the US and Canadian markets from a major pharmaceutical company on or before March 14, 2011. While the Company is expecting to close this acquisition, there is no assurance that such a transaction will be completed.

### **About Merus Labs International Inc.**

Merus is a specialty pharmaceutical company engaged in acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in the North American pharmaceutical markets and its access to capital to acquire and license niche branded products in Canada and United States. Merus further enhances the sale and distribution of these products by introduction of a focused marketing and promotion plan.

### **Forward-looking Statements:**

*This press release may contain forward-looking statements that involve risks and uncertainties. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology including "could", "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" and the negative of these terms or other comparable terminology. While these forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment regarding the direction of our business, actual results will almost*

*always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this report. Except as required by applicable law, we do not intend to update any of the forward-looking statements so as to conform these statements to actual results. Investors should refer to the risks disclosed in the Company's reports filed from time to time with securities regulatory authorities.*

For further information please contact:

**Dr. Error! Reference source not found.**, Chief  
Executive Officer

Merus Labs International Inc.

Tel: (604) 805-7783

[adoroudian@meruslabs.com](mailto:adoroudian@meruslabs.com)